Nafamostat works by inhibiting the activity of enzymes called serine proteases, which play a role in blood coagulation, inflammation, and cell signaling. By inhibiting these enzymes, nafamostat can prevent blood clots from forming and reduce inflammation.
In addition to its use as an anticoagulant and anti-inflammatory agent, nafamostat has also been studied for its potential antiviral activity against a number of viruses, including SARS-CoV-2, the virus that causes COVID-19. Some research suggests that nafamostat may be effective in preventing the entry of the virus into host cells.
